AcquisitionOther
Allarity Therapeutics, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Allarity Therapeutics, Inc. -> target · $20M
The Company has a mature portfolio of five drug candidates, including: Stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; Dovitinib, a pan-TKI being prepared for an NDA submission to the FDA for the 3 rd line treatment of renal cell carcin
Open source record (SEC) ↗